ClinicalTrials.gg
Active, not recruitingNCT03566160Updated Oct 2, 2026

Pilot Study for Evaluation of Cryobiopsy and Correlation With Standard Forceps Biopsy

An interventional study of Cryobiopsy probe, administered to study participants in Gastrointestinal Disease, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

How we know

Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Gastrointestinal Diseases with a site in United States — 32 open to participants now, 42 under way, 5 of them phase 3. Gastrointestinal Diseases · United States.

Planned enrollment
104th of 141
30 · median 90
Started
2018
with 10 others
No phase
63 of 200
13 open now
Primary completion
2028-12
later than 32 of 41 live
Registered
118th of 200
by date
Lead sponsor
6 of 200
Massachusetts General Hospital

Among the 200 studies in Gastrointestinal Diseases with a site in United States, this one is the 104th largest by planned enrollment of the 141 interventional ones that give a count, is one of 11 that started in 2018, is one of 63 with no phase, reaches primary completion later than 32 of the 41 other live ones, and was the 118th registered.

Gastrointestinal Diseases

549 studies on the registry are indexed under Gastrointestinal Diseases; 102 are open to participants now.

Browse Gastrointestinal Diseases studies →

Open to participants now

32 of the 200 studies in Gastrointestinal Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Gastrointestinal Diseases studies recruiting now, 30 (45%) set no upper age limit and 23 (35%) stop at 75 or younger; 19 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Gastrointestinal Diseases with a site in United States, or all of them as a file.
02

Study summary

Environmental enteric dysfunction (EED) is a poorly understood condition characterized by intestinal inflammation and loss of barrier function that is prevalent in regions of the world with inadequate sanitation and hygiene. EED is a major driver of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection, affecting 25% of all children globally and causing over a million deaths each year.

Progress towards understanding EED and developing effective interventions has been hampered by an inability to evaluate the intestinal mucosa of populations in impoverished regions of the world where this condition is endemic. In order to prevent the deleterious and permanent sequelae of the disease, there is a need for effective diagnosis and intervention to be implemented in EED patients before the age of 2. Currently, the only means for directly evaluating the intestine is endoscopy with mucosal biopsy. Unfortunately, endoscopy is untenable for the study of EED because of limited resources and the high cost. As a result, there is a clear, unmet need for a less invasive tool that can be used in low-and-middle-income-countries (LMICs) to evaluate the intestine in population with EED.

This work is supported by a grant from The Bill and Melinda Gates Foundation (BMGF). The overall goal is to provide a minimally invasive means of obtaining detailed infantile intestinal tissue information that is needed for the development of effective EED interventions. Obtaining biopsies will play a critical role in gathering the detailed intestinal tissue information.

The purpose of this study is to explore the feasibility of utilizing a cryobiopsy probe to obtain biopsies in adults.

Read the detailed description

This study will test the capacity of a gastrointestinal tract cryobiopsy probe that Tearney Lab investigators have designed to obtain biopsies from the upper GI tract.

A total of twenty (20) participants, adults 18 years of age and older, scheduled for elective esophagogastroduodenoscopy with biopsy will be enrolled in this study.

A maximum of 3 cryobiopsies per subject will be collected. After each cryobiopsy is complete, the endoscopist will then take 1 standard forceps biopsy from the area adjacent to where cryobiopsy was performed. A maximum of 3 standard forceps biopsies for research purposes only will be taken. Biopsy collection will be performed at the discretion of the endoscopist. The standard forceps biopsy sites will also be monitored directly throughout the entire experimental procedure. The total experimental procedure time will not exceed 15 minutes.

03

Conditions studied

  • Gastrointestinal Disease

Keywords

  • Biopsy
  • EGD
  • Endoscopy
  • Cryobiopsy
  • OCT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for an elective esophagogastroduodenoscopy with .
  • 18 years of age or older.
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • According to standard of care.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cryobiopsy probe as a tool for biopsy

    Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.

    Device: Cryobiopsy probe, administered to study participants

Interventions

  • DeviceCryobiopsy probe, administered to study participants

    Cryobiopsy probe as a tool for gastrointestinal biopsy

06

What researchers measure

Primary outcomes

  1. Evaluation of Cryobiopsy probe

    Evaluation of Cryobiopsy probe in obtaining tissue samples over .5mm

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Dec 2028, 123 months after the start.

Of 127 non-industry interventional studies with no phase under Gastrointestinal Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 123 months is above that.

Counting every sponsor, half of 149 studies reached it within 24 months; a quarter within 10 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2027 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jun 25, 2018
StartActual
Sep 5, 2018
Primary completionEst.
Dec 30, 2028was Dec 2026
CompletionEst.
Dec 30, 2030was Dec 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2026→Dec 30, 2028
Oct 2, 2026
Study completion
Dec 30, 2027→Dec 30, 2030
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Dec 30, 2026→Dec 30, 2028
    Study completion Dec 30, 2027→Dec 30, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03566160
Collaborators
Bill and Melinda Gates Foundation
Responsible party
Guillermo Tearney (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jun 25, 2018
Start date
Sep 5, 2018
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Oct 2, 2026

Study contacts

Guillermo Tearney, M.D PhD.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion